Driouk et al. demonstrated the efficacy of NKG2D-targeting CAR-T cells against AML cell lines and reported an upregulation of 41BB and other costimulatory molecules by CD8+ NKG2D CAR-T cells compared to control T cells [202]. Here, CD8A is linked to acute myeloid leukemia.